$TNGX News

HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $68

Tango Therapeutics: Promising Early Data, But A Long Road Ahead

Guggenheim Maintains Buy on Tango Therapeutics, Raises Price Target to $35

Tango Therapeutics Files Prospectus For Up To $400M Common Stock Offering

Tango Therapeutics Q2 EPS $(0.37) Misses $(0.32) Estimate

Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $40

JP Morgan Initiates Coverage On Tango Therapeutics with Overweight Rating, Announces Price Target of $46

Canaccord Genuity Maintains Buy on Tango Therapeutics, Raises Price Target to $46

Jefferies Upgrades Tango Therapeutics to Buy, Raises Price Target to $60

HC Wainwright & Co. Maintains Buy on Tango Therapeutics, Raises Price Target to $66

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer Transcript

Tango Therapeutics Launches $500M Common Stock Offering

Tango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - Slideshow

Why Is Tango Therapeutics Stock Soaring Monday?

Tango Therapeutics Announces Initial Data From Ongoing Phase 1/2 Study Of Vopimetostat In Combination With Revolution Medicines' RAS(ON) Inhibitors In Patients With MTAP-Deleted And RAS-Mutant Metastatic PDAC

Acuta Capital Bet on Erasca (ERAS) and Targeted Cancer Treatments With a 354,575 Share Buy

Mizuho Maintains Outperform on Tango Therapeutics, Raises Price Target to $30

Piper Sandler Downgrades Tango Therapeutics to Neutral, Raises Price Target to $24

Jefferies Downgrades Tango Therapeutics to Hold, Raises Price Target to $27

Leerink Partners Maintains Outperform on Tango Therapeutics, Raises Price Target to $55